International Journal of Myeloma
Online ISSN : 2187-3143
Volume 12, Issue 4
Displaying 1-1 of 1 articles from this issue
ORIGINAL
  • Kosei MATSUE, Junya NAKAMURA, Devender DHANDA, T. Kim LE, Tao GU, Jill ...
    Article type: ORIGINAL
    2022 Volume 12 Issue 4 Pages 25-32
    Published: 2022
    Released on J-STAGE: June 17, 2022
    JOURNAL FREE ACCESS

    The KarMMa-Real World (RW) study showed treatment variability and suboptimal outcomes for triple-class exposed (TCE) patients with relapsed or refractory multiple myeloma (RRMM). This retrospective analysis of de-identified electronic health records from the KarMMa-RW study evaluated characteristics, treatments, and outcomes for TCE patients with RRMM in two hospitals in Japan. Date of refractory treatment status was the index date. Patients with a new post-index treatment (RRMM-Treatment) or no post-index treatment (RRMM-No Treatment) were followed until death or last known date alive. Patient characteristics, post-index treatments, overall response rate (ORR), time to response (TTR), duration of response (DOR), overall survival (OS), and progression-free survival (PFS) were summarized. Twenty-two patients were eligible for analysis (RRMM-Treatment, n = 14; and RRMM-No Treatment, n = 8). The RRMM-Treatment group had an ORR of 21.4%, median TTR of 22 days, and median DOR of 180 days. Median OS was 20.5 months (95% CI 20.5–not estimable) for the RRMM-Treatment group and 8.9 months (95% CI 0.1–22.7) for the RRMM-No Treatment group. Median PFS was 4.8 months (95% CI 1.9–6.7) for the RRMM-Treatment group. We observed a substantial disease burden, suggesting a need for more effective treatment options for TCE Japanese patients with RRMM.

    Download PDF (441K)
feedback
Top